Are peptides legal in 2026?

Some peptides are legal to prescribe and compound in 2026, and most of the ones people search for are not. As of October 18, 2026, a licensed 503A pharmacy may compound sermorelin, bremelanotide (PT-141), oxytocin and GHK-Cu for the skin for an individual prescription. BPC-157, TB-500, MOTS-c, KPV, CJC-1295, ipamorelin and the rest of the popular list still can’t be compounded, even after the FDA’s April changes and the July advisory committee votes. Here is what each step did and didn’t change.

How a peptide becomes legal to prescribe

There are only two lawful ways to get a peptide as a medicine in the US.

An FDA-approved drug. Some peptides went through the full approval process: Vyleesi (bremelanotide) for low sexual desire in premenopausal women, Egrifta SV (tesamorelin) for belly fat in adults with HIV-related lipodystrophy, and the GLP-1 medications such as Wegovy and Zepbound. A clinician can prescribe these, and using them for anything else is off-label.

A compounded prescription. Under section 503A of the Food, Drug, and Cosmetic Act, a state-licensed pharmacy can prepare a medicine for one patient’s prescription, but only from a bulk ingredient that meets one of three tests: it has a USP or National Formulary monograph, it is a component of an FDA-approved drug, or it is on the FDA’s 503A bulks list (FDA interim policy). While that list is still being built, the FDA says it won’t act against pharmacies that compound with substances in its Category 1 (nominated with enough support and under review), as long as the ingredient comes from a registered manufacturer with a certificate of analysis.

Two other categories matter. Category 2 holds substances the FDA says raise significant safety risks. Category 3 holds substances nominated without enough support. Neither can be compounded under the interim policy. A substance in no category at all can’t be compounded either, unless it passes one of the three tests above.

Everything sold as a “research peptide”, with a label saying it is for laboratory research only, sits outside both routes. The FDA has called such products unapproved new drugs in warning letters, including one in June 2023 over injectable and nasal BPC-157 and TB-500 sold this way (FDA).

The 2026 timeline

April: off Category 2, but not onto anything

In April 2026, after the groups that nominated them withdrew their nominations, the FDA moved nine peptides off Category 2 and onto a list of substances “nominated but withdrawn” on its safety-risks page. Some coverage read this as the FDA “easing” its stance. It didn’t make any of them legal to compound. A withdrawn nomination leaves a peptide in no category, and none of these nine has a USP monograph, an approved-drug component or a place on the bulks list. Under the January 2025 interim policy, a substance nominated after January 7, 2025 isn’t placed in Category 1, so a fresh nomination wouldn’t open the door either.

The same page still carries the FDA’s safety notes for each one. For BPC-157 it says the agency has “no, or only limited, safety-related information for the proposed routes of administration”. For TB-500, KPV and MOTS-c it says it has not identified any human exposure data on drug products containing them.

July: the advisory committee votes

On July 23 and 24, 2026, the FDA’s Pharmacy Compounding Advisory Committee considered whether seven peptides should go on the 503A bulks list, each for the uses its nominator proposed (Federal Register). The FDA has not posted minutes or official vote counts. Law firms that followed the meeting reported these results (McDermott):

Advisory committee votes are advice. To put a peptide on the bulks list, the FDA has to publish a proposed rule in the Federal Register, take comments and issue a final rule. As of October 18, 2026, it has done none of that for any of the seven, and its categories list is still the version updated May 14, 2026.

Still waiting: LL-37 and injectable GHK-Cu

The FDA has said it plans to consult the committee on GHK-Cu, and on LL-37, before the end of February 2027. Until then, injectable GHK-Cu and LL-37 sit in no category and can’t be compounded.

Where each peptide stands in October 2026

Sermorelin is the case people most often get wrong. The FDA approved it as Geref, and its maker discontinued it in 2008. In 2013 the FDA determined that Geref was not withdrawn for safety or effectiveness (Federal Register), which keeps sermorelin a component of an approved drug and lets a pharmacy compound it. We explain the details in is sermorelin legal and how is it prescribed.

Tesamorelin goes the other way. It is FDA-approved, but its application was deemed a biologics license on March 23, 2020 (Drugs@FDA), and 503A compounding covers drugs, not biologics. A compounded tesamorelin offer is not lawful.

Legal to compound isn’t the same as approved

A compounded peptide is not an FDA-approved drug, even when the pharmacy is allowed to make it. The FDA does not review compounded medicines for safety, effectiveness or quality before they are sold. Using sermorelin for energy or aging, oxytocin for stress or sleep, or PT-141 in men is off-label: no FDA review stands behind those uses. A licensed clinician should weigh that with you before prescribing.

What about peptides labeled for research only?

Online shops that sell vials “for research” without a prescription are not pharmacies, and the label doesn’t make the product legal to sell for people to use. Buying these for personal use is unsafe and unregulated. No prescriber checks whether it suits you, no licensed pharmacy answers for what is in the vial, and no one has checked its identity, strength, sterility or contamination. The FDA’s warning letters on BPC-157, TB-500, retatrutide and cagrilintide sold this way all treat them as unapproved new drugs. Our guide to whether peptides are safe covers the risks.

The bottom line

In October 2026, the peptides you can get legally with a prescription are the FDA-approved ones (such as Vyleesi, Egrifta SV and the GLP-1s) and four that pharmacies may compound: sermorelin, PT-141, oxytocin and topical GHK-Cu. The April removals and the July votes moved BPC-157 and six others closer to a decision, but none of them can be compounded until the FDA acts. If you want peptide therapy, see our ranked list of licensed peptide providers or the peptides hub, and ask any provider which pharmacy will fill your prescription.